M. Dalén, F. Biancari, A. Perrotti, G. Mariscalco, F. Onorati, G. Faggian, I. Franzese, A. Salsano, F. Santini, V.G. Ruggieri, D. Maselli, S. Nardella, G. Santarpino, T. Fischlein, M. Saccocci, M. Zanobini, F. Musumeci, R. Gherli, A.S. Rubino, M. De Feo, C. Bancone, F. Nicolini, E.-M. Kinnunen, T. Tauriainen, D. Reichart, T. Demal, G. Gatti, S. Khodabandeh, M. Holm, Infectious complications in patients receiving ticagrelor or clopidogrel before coronary artery bypass grafting, Journal of Hospital Infection, Volume 104, Issue 2, 2020, Pages 236-238, ISSN 0195-6701, https://doi.org/10.1016/j.jhin.2019.09.018
Infectious complications in patients receiving ticagrelor or clopidogrel before coronary artery bypass grafting
|Author:||Dalén, M.1,2; Biancari, F.3,4,5; E-CABG Study Group Collaborators|
1Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
2Department of Cardiac Surgery, Karolinska University Hospital, Stockholm, Sweden
3Heart Center, Turku University Hospital, University of Turku, Turku, Finland
4Department of Surgery, University of Turku, Turku, Finland
5Department of Surgery, University of Oulu, Oulu, Finland
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe202003238749
|Publish Date:|| 2020-09-26
The antiplatelet agent ticagrelor has recently been found to have bactericidal activity, demonstrated in vitro and in an in vivo mouse model, which warrants further clinical investigations. The aim of this study was to evaluate infectious complications after coronary artery bypass grafting in patients pre-operatively treated with ticagrelor or clopidogrel. In a multi-centre trial, all adult patients who were pre-operatively treated with ticagrelor or clopidogrel prior to isolated primary coronary artery bypass grafting were eligible. Propensity score matching was used. Outcome measures were any sternal wound infection, deep sternal wound infection, and any in-hospital use of postoperative antibiotics. Of 2311 patients who were included, 1293 (55.9%) received clopidogrel and 1018 (44.1%) ticagrelor pre-operatively. In both overall and propensity score matched analyses, ticagrelor was associated with a similar incidence of infectious complications compared to clopidogrel. Our findings do not support a clinically relevant bactericidal effect of ticagrelor in patients undergoing coronary artery bypass grafting.
Journal of hospital infection
|Pages:||236 - 238|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3126 Surgery, anesthesiology, intensive care, radiology
Magnus Dalén was financially supported by a research grant from Karolinska Institutet (grant number 2018-01278).
© 2019 The Healthcare Infection Society. Published by Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.